Latest B-cell chronic lymphocytic leukemia Stories
FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND
New Facility Poised to Accelerate the Research and Development of Personalized Cellular Cancer Therapies PHILADELPHIA, Sept.
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept.
Input will help shape the role of public contributions to orphan drug approvals OTTAWA, Aug.
- IMBRUVICA Net Product Revenue Increased to $109.5 million for the Second Quarter of 2014 - SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
FLINT, Mich., July 28, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig(®) tablets.
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S.
Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics,
SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S.
- A woman chauffeur.
- A woman who operates an automobile.